Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Not ONE insider buy all year

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Jun 16, 2017 4:48pm

156 Views

Post# 26372529

RE:Not ONE insider buy all year

No one is happy but you can at least state the facts we know.

"Also, further to its press release of March 16, 2017, the Company wishes to provide additional information regarding the investor relations engagements of Hybrid Financial Inc. ("Hybrid") and Stern Investor Relations, Inc. ("Stern"). Under the terms of the engagements, COTI expects to pay aggregate fees of $120,000 over the initial period of the agreements."

<< Previous

Bullboard Posts

Next >>

Transportation technology stock secures second major contract in a week